201 related articles for article (PubMed ID: 16237064)
21. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Fowler DH; Odom J; Steinberg SM; Chow CK; Foley J; Kogan Y; Hou J; Gea-Banacloche J; Sportes C; Pavletic S; Leitman S; Read EJ; Carter C; Kolstad A; Fox R; Beatty GL; Vonderheide RH; Levine BL; June CH; Gress RE; Bishop MR
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1150-60. PubMed ID: 17085308
[TBL] [Abstract][Full Text] [Related]
22. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
Zhao J; Zhao XY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
[TBL] [Abstract][Full Text] [Related]
23. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
24. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation.
Lin Y; Wang B; Shan W; Tan Y; Feng J; Xu L; Wang L; Han B; Zhang M; Yu J; Yu X; Huang H
Clin Immunol; 2018 Feb; 187():122-131. PubMed ID: 29132870
[TBL] [Abstract][Full Text] [Related]
26. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
27. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Fowler DH; Mossoba ME; Steinberg SM; Halverson DC; Stroncek D; Khuu HM; Hakim FT; Castiello L; Sabatino M; Leitman SF; Mariotti J; Gea-Banacloche JC; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Rowley S; Goy A; Donato M; Korngold R; Pecora A; Levine BL; June CH; Gress RE; Bishop MR
Blood; 2013 Apr; 121(15):2864-74. PubMed ID: 23426943
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Anderson LD; Petropoulos D; Everse LA; Mullen CA
Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
[TBL] [Abstract][Full Text] [Related]
31. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
32. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
33. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
[TBL] [Abstract][Full Text] [Related]
34. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
35. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease.
Anderson LD; Savary CA; Mullen CA
Blood; 2000 Apr; 95(7):2426-33. PubMed ID: 10733517
[TBL] [Abstract][Full Text] [Related]
36. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.
Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M
J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048
[TBL] [Abstract][Full Text] [Related]
37. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
Aharoni R; Schlegel PG; Teitelbaum D; Roikhel-Karpov O; Chen Y; Arnon R; Sela M; Chao NJ
Immunol Lett; 1997 Jul; 58(2):79-87. PubMed ID: 9271317
[TBL] [Abstract][Full Text] [Related]
38. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.
Nikolic B; Lee S; Bronson RT; Grusby MJ; Sykes M
J Clin Invest; 2000 May; 105(9):1289-98. PubMed ID: 10792004
[TBL] [Abstract][Full Text] [Related]
39. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
40. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
